Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Pharmaceuticals company response to activist approach
We advised the company on an activist approach
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
PracticeTek merger with Integrated Practice Solutions and related financing
We advised Lightyear Capital and PracticeTek on the transaction to form a leading U.S. retail healthcare solutions provider
Abcam $5.7 billion acquisition by Danaher
We advised financial advisers to Abcam on the transaction
SSI Strategy acquisition of NDA Group
We advised SSI Strategy on the acquisition
Allurion Technologies merger with Compute Health Acquisition
We advised the capital markets adviser on the de-SPAC transaction
Immedica Pharma acquisition of pegzilarginase assets from Aeglea
We advised Immedica on the transaction
Centogene strategic collaboration with Lifera
We are advising Centogene on its joint venture with and convertible debt investment by Lifera